One Lambda, Inc.

One Lambda, Inc., a for-profit manufacturer of immunogenetic and transplant diagnostic testing reagents headquartered in Canoga Park, California, operates as a subsidiary of Thermo Electron Corporation and supplies specialized medical testing products to federal healthcare and research institutions exclusively as a prime contractor across full-and-open procurements with no set-aside designations.

One Lambda's capability portfolio centers on human leukocyte antigen (HLA) typing reagents, antibody screening kits, laboratory diagnostic supplies, and laboratory information system software maintenance. Recent representative work includes a $615,447 purchase order from the NIH Clinical Center awarded June 1, 2026, for HLA typing and antibody screening reagents to support the HLA Lab on a regular basis, a $887,127 BPA call from the Defense Health Agency issued February 10, 2026, to provide organ transplant supplies to Walter Reed National Military Medical Center, and a $1.26 million delivery order from Veterans Integrated Service Network 23 dated October 1, 2025, for reagents under a new $6.9 million indefinite delivery contract running through September 30, 2030. One Lambda also provides HistoTrac laboratory information system maintenance to multiple federal agencies — a $28,611 purchase order from the Defense Health Agency (March 2026, completion March 2029) and a $62,273 purchase order from the NIH Clinical Center (December 2023, completion December 2025) exemplify this recurring software support mission.

Customer concentration is distributed across military healthcare and VA networks. The Defense Health Agency leads by potential value at $26.4 million across 27 awards, followed closely by Veterans Integrated Service Network 23 at $22.6 million across 43 awards and the Bureau of Medicine and Surgery at $21.7 million across 55 awards. Together these three customers account for approximately 95% of One Lambda's combined potential value in the source data. The NIH Clinical Center and Veterans Integrated Service Network 9 round out the top five. The divergence between award count and dollar magnitude reflects One Lambda's positioning: VISN 23 places many smaller delivery orders under IDIQs while DHA concentrates dollars in fewer, larger BPA calls.

One Lambda holds two significant parent vehicles. A $7.5 million single-award Blanket Purchase Agreement with the Defense Health Agency (awarded December 6, 2024, completion December 8, 2029) serves as the master ordering vehicle for laboratory supplies across federal healthcare facilities, with 11 task orders totaling $2.2 million in combined potential value in the source data. A $6.9 million single-award Indefinite Delivery Contract with Veterans Integrated Service Network 23 (awarded October 1, 2025, completion September 30, 2030) is structured in five one-year ordering periods and has already generated one delivery order ($1.26 million, October 2025). Older vehicles, including Blanket Purchase Agreements HT001415A0049 and HT001420A0015 with DHA, continue to generate task orders at declining rates.

Activity has contracted year over year — six awards in 2022 and 2023, seven in 2024, five in 2025, and four in the first half of 2026 — but the most recent awards are recent-term vehicles with long runways. Seven awards totaling $3.2 million in combined potential value complete within the next twenty-four months, creating moderate recompete exposure. One Lambda operates exclusively as a prime contractor (349 awards, 100% prime posture) and serves 18 distinct customer agencies, but customer concentration among military and VA healthcare organizations anchors the portfolio. NAICS distribution reflects the reagent and diagnostic instrument focus: Research and Development in Biotechnology accounts for 94 awards, In-Vitro Diagnostic Substance Manufacturing for 49 awards, and Analytical Laboratory Instrument Manufacturing for 10 awards. One Lambda competes in full-and-open procurements and has not pursued SBA set-aside certifications across its federal footprint.